Kirkland Advises on ImmuneOnco Biopharmaceuticals Hong Kong IPO

Kirkland & Ellis represented the joint sponsors and underwriters on the global offering and listing of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKSE: 1541), a leading science-driven biotechnology company dedicated to the development of immuno-oncology therapies in China, on the Hong Kong Exchanges and Clearing Limited on September 5, 2023.

ImmuneOnco is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. The IPO raised approximately $40.7 million. The joint sponsors are Morgan Stanley Asia Limited and  China International Capital Corporation Hong Kong Securities Limited.